Good News Israel presents success for treatment of back pain; sealing up after surgery and much more.

By: Michael Ordman

ISRAEL’S MEDICAL ACHIEVEMENTS

Success for treatment of back pain

Israel’s Nervomatrix has reported success from independent controlled trials of its hyper-stimulation pulse device for treating lower back pain. The study on 28 patients at Belgian’s Free University of Brussels obtained significant pain relief after 4 treatments compared to a control group.

http://www.globes.co.il/en/article-nervomatrix-reports-back-pain-system-trial-success-1001059763

Protection against future flu strains

Israel’s BiondVax has published independent tests of trials showing that its M-001 Universal Flu vaccinations given 3 years ago have protected patients from flu strains that only came into existence well after the vaccine was administered.

http://www.biondvax.com/2015/08/03/independent-results-show-that-biondvaxs-universal-flu-vaccine-administered-in-a-trial-3-years-ago-improves-immunogenicity-against-current-flu-h3n2-epidemic/

Sealing up after surgery

Israel’s LifeBond has developed LifeSeal – a sealant to greatly reduce surgical leaks, which are associated with potential infections and other serious complications, risking the lives of hundreds of thousands every year. LifeBond has just raised $27 million of funding.

http://jewishbusinessnews.com/2015/08/09/israeli-biomed-startup-lifebond-raises-27-million-to-help-tissue-heal-after-surgery/

2015 WEF Technology Pioneers

Three Israeli companies were chosen by the World Economic Forum (WEF) in its 2015 list of 14 Technology Pioneers in the Life Science and Health category. ElMindA’s Brain Network Activation identifies brain damage. Consumer Physics’s SCIO is a chemical analyzer. Novocure uses electric fields to treat solid tumors.

http://www.israel21c.org/elminda-consumer-physics-novocure-awarded-technology-pioneer-by-world-body/

Robotic needle steering

Israeli startup XACT Robotics developed a robotic system for needle steering, for use in biopsies and ablations, or to inject medications in specific areas of the body. The first application of XACT’s technology will be for biopsies in lung tissue. XACT has just raised $5 million to fund US trials.

http://www.globes.co.il/en/article-xact-robotics-raises-5m-1001059641

Fast track for Muscular Dystrophy treatment

The US FDA has given fast track approval to Israel’s BioBlast for its Cabaletta treatment for two rare and currently untreatable conditions – oculopharyngeal muscular dystrophy (OPMD) and spinocerebellar ataxia type 3 (SCA3).

http://www.israel21c.org/drug-for-rare-muscular-dystrophy-fast-tracked/

Click here for all of this week’s Good News from Israel.